Diligence memo · auto-generated · as of July 2, 2026
Prometheus Therapeutics Inc.
Prometheus Therapeutics Inc. looks under-valued against its niche peers and is active on financing cadence.
Businessfiled
Prometheus Therapeutics Inc. operates in Pharma, based in MIRAMAR.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Prometheus Therapeutics Inc. has raised $8.9M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $8.2M on 2023-01-31.
Most recent recorded round closed around 2025-10-28.
Valuation (modeled)modeled
Provath models Prometheus Therapeutics Inc. at approximately $370K (range $149K–$589K). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.02× the median modeled value of Series A Pharma companies in 2025–2027 (9 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 12 months.
Last raise 8 mo ago; this sector typically re-raises about every 16 months.
Raising on or ahead of the sector's normal rhythm.
The last round was 19.6× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 64% of Pharma peers (310 compared).
Modeled value ranks above 18% of those peers.
Closest niche peers: Neela Therapeutics, Inc., AeroRx Therapeutics, Inc., Cirrus Therapeutics, Inc., Kamau Therapeutics, Inc., Merge Bio Therapeutics Corp.
Peoplefiled
7 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.